ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Income Before Tax

Profit after all operating and non-operating items but before income tax.

ProQR Therapeutics N.V.NASDAQ: PRQR

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -€13.6M, compared with -€10.08M a year earlier. Trailing-twelve-month income before tax was -€45.61M.

Context

  • Income before tax amounted to 265.1% of revenue in FY2025, up 117.2 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -€13.6M or moves back toward the trailing-twelve-month quarterly average of -€11.4M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€13.6M-54.0% QoQ
Last fiscal yearDec 2025
-€40.5M-44.9% YoY
LTMMar 2026
-€45.61M-50.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.0%——
1 year-44.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

EUR · from the income statement

Latest · FY2025
(40.5M) EUR
Year-over-year change
-44.9%

Income Before Tax vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -50.1% is the 8th highest of 11, against a peer median of -18.1%.
  • Income before tax amounts to 339.3% of revenue for PRQR, versus a peer median of 749.8%.
PRQR Competitors
Income Before Tax for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MREOMereo BioPharma Group plcLTM Mar 2026-$35.79M USD+25.0%—7158.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€45.61M EUR-50.1%—339.3%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$51.99M USD-12.6%——
IMMPImmutep LimitedFY2025-A$61.43M AUD-43.8%—1218.0%
ZURAZura Bio LimitedLTM Mar 2026-$75.43M USD-21.5%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$78.67M USD-14.7%—173.5%
EDITEditas Medicine, Inc.LTM Mar 2026-$108.95M USD+56.6%—281.6%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$114.59M USD-108.1%——
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-$149.7M USD-169.1%—68.7%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-$165.16M USD-793.7%—2878.3%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M USD+31.0%——
Peer median (excluding PRQR) —-18.1%—749.8%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.